Markus Liew-Littorin

Markus Liew-Littorin

Auto-generated profile, based on publicly available information

Markus Liew-Littorin

Division of Hematology, Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2026 in Nature
Verified
Journal Article
Open access
PDF file
YOYotaro Ochi
Yotaro Ochi
MLMarkus Liew-Littorin
Markus Liew-Littorin
YNYasuhito Nannya
Yasuhito Nannya
SBSofia Bengtzen
Sofia Bengtzen
BPBenedicte Piauger
Benedicte Piauger
SOSeishi Ogawa
Seishi Ogawa
Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML1,2,3,4,5,6,7,8; however, the role of epigenetic alterations in these respects has been investigated less extensively. Here we use ATAC-seq (assay for transposase-accessible chromatin with sequencing) in a cohort of 1,563 individuals with a recent diagnosis of AML (the ‘eCHROMA’ cohort) to show that AML can be classified into 16 subgroups on the basis of chromatin accessibility profiles. Multiomics analyses of gene mutations, the transcriptome, DNA methylation and histone marks show that these ATAC subgroups exhibit distinct driver mutations, differentiation states, gene expression, DNA methylation and super-enhancer profiles, and are also associated with clinical outcomes. These findings were validated in independent cohorts. Single-cell ATAC sequencing reveals that all leukaemic cells in each subgroup share a common chromatin accessibility profile, which suggests that subgroup-specific epigenomic fingerprints underlie the ATAC-based classification. Mechanistically, the subgroups have distinct gene-regulatory networks that are driven by the activities of key transcription factors in haematopoiesis, and in which subgroup-specific super-enhancers have a pivotal role. Multiomics single-cell analysis further reveals deregulated trajectories of differentiation coupled with chromatin accessibility and gene expression. Notably, ATAC subgroups have an independent prognostic effect, compared with genomic classification, and are associated with particular drug sensitivities. In summary, ATAC-based chromatin profiling, combined with multiomics data, provides insights into AML pathogenesis beyond genomics and constitutes a valuable resource for AML research.

24 July 2025 in European Journal of Haematology
Verified
Journal Article
Open access
MLMarkus Liew‐Littorin
Markus Liew‐Littorin
LDLinn Deleskog‐Spångberg
Linn Deleskog‐Spångberg
SDStefan Deneberg
Stefan Deneberg
JJJudit Janosi
Judit Janosi
VLVladimir Lazarevic
Vladimir Lazarevic
SLSören Lehmann
Sören Lehmann
Refractory acute myeloblastic leukemia (AML) is poorly studied. In this study, we characterized primary refractory AML and investigated treatment and outcome in a population‐based setting. Based on all AML patients receiving intensive induction therapy at 12 Swedish hospitals from 2011 to 2018 (N = 1221), we identified 306 patients that failed to achieve composite complete remission (CRc) after first‐line therapy. Two‐hundred‐sixteen (71%) of these patients received salvage treatment with intensive chemotherapy (ICT), of which 126 (58%) achieved CRc and 85 (39%) underwent allogeneic stem cell transplantation (HSCT). One‐ and 3‐year overall survival (OS) in patients receiving salvage ICT were 56.8% and 28.9%, respectively. Secondary AML and adverse ELN risk were associated with worse OS after salvage ICT, while fludarabine‐based FAIDA versus amsacrine‐based ACE salvage and HSCT were associated with better OS. Three‐year OS after first or second salvage chemotherapy, followed by HSCT were 55% and 71%, respectively. Refractory patients responding to salvage ICT showed only a nonsignificant trend toward inferior OS compared to patients in CRc after the first cycle. In conclusion, refractory AML patients eligible for further intensive therapy have a reasonable chance of obtaining remission and long‐term survival when followed by HSCT. The results can serve as a basis for evaluation of new treatments in refractory AML.